Laboratory Corp. of America Holdings (LH)

170.80
NYSE : Health Services
Prev Close 167.99
Day Low/High 169.18 / 171.74
52 Wk Low/High 119.38 / 190.00
Avg Volume 779.40K
Exchange NYSE
Shares Outstanding 98.50M
Market Cap 16.55B
EPS 8.70
P/E Ratio 19.09
Div & Yield N.A. (N.A)

Latest News

Faruqi & Faruqi, LLP Is Investigating Laboratory Corporation Of America Holdings (LH) On Behalf Of Its Shareholders

Faruqi & Faruqi, LLP Is Investigating Laboratory Corporation Of America Holdings (LH) On Behalf Of Its Shareholders

NEW YORK, June 6, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential misconduct at Laboratory Corporation of America Holdings ("LabCorp" or the "Company") (NYSE:LH).

LabCorp Announces New Leadership Roles

LabCorp Announces New Leadership Roles

LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that David P.

LabCorp Announces New Term Loan Facility

LabCorp Announces New Term Loan Facility

On June 3, 2019, LabCorp® (NYSE: LH) entered into a new Term Loan Credit Agreement, which provides for a two-year term loan credit facility in the principal amount of $850 million (the "New Term Loan Facility").

LabCorp And Envigo Complete Innovative Transactions

LabCorp And Envigo Complete Innovative Transactions

LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, and Envigo, a leading provider of research models and services, today announced that they have completed previously announced transactions that...

LabCorp Announces Availability Of New QIAGEN Therascreen FGFR Mutation Analysis Companion Diagnostic For Bladder Cancer

LabCorp Announces Availability Of New QIAGEN Therascreen FGFR Mutation Analysis Companion Diagnostic For Bladder Cancer

LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the availability of a newly-approved companion diagnostic by the U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APO, CKH, CLCT, EARN, ERII, HCI, INN, KEN, LH, PBF, PPDF, PXLW, SHAK, TS Downgrades: D, EPAY, GSIT, HPP, REGI, RIVE, TDC, TYPE, VIRT, VRAY Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

LabCorp To Webcast Its Annual Meeting Of Shareholders

LabCorp To Webcast Its Annual Meeting Of Shareholders

LabCorp® (NYSE: LH) today announced that its Annual Meeting of Shareholders will be webcast live beginning May 9, 2019, at 9:00 a.

LabCorp Announces 2019 First Quarter Results And Increases 2019 Earnings Guidance

LabCorp Announces 2019 First Quarter Results And Increases 2019 Earnings Guidance

LabCorp® (or the Company) (NYSE: LH) today announced results for the first quarter ended March 31, 2019, and increased 2019 earnings guidance.

LabCorp And Envigo Sign Innovative Agreement To Expand Covance's Nonclinical Drug Development Capabilities And Create An Independent Research Models Provider

LabCorp And Envigo Sign Innovative Agreement To Expand Covance's Nonclinical Drug Development Capabilities And Create An Independent Research Models Provider

LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, and Envigo, a leading provider of nonclinical contract research services and research models, today announced that LabCorp's Covance Drug...

Sherwin-Williams Shareholders Elect New Directors

Sherwin-Williams Shareholders Elect New Directors

Kerrii B. Anderson, former CEO and President of Wendy's International, Inc., and Jeff M. Fettig, former Chairman and CEO of Whirlpool Corporation, join the Board

LabCorp To Announce First Quarter Financial Results On April 30, 2019

LabCorp To Announce First Quarter Financial Results On April 30, 2019

LabCorp® (NYSE: LH) will release its first quarter of 2019 financial results before the market opens on Tuesday, April 30, 2019, followed by a conference call and webcast beginning at 9:00 a.

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Earns 100 Percent On Human Rights Campaign Foundation's 17th Annual Scorecard On LGBTQ Workplace Equality

LabCorp Earns 100 Percent On Human Rights Campaign Foundation's 17th Annual Scorecard On LGBTQ Workplace Equality

LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it received a perfect score of 100 on the 2019 Corporate Equality Index (CEI), the nation's premier benchmarking survey and...

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest

LabCorp® (NYSE: LH) announced today that for the period of March 11, 2019 to Sept.

LabCorp Is Scheduled To Present At The 2019 Barclays Global Healthcare Conference

LabCorp Is Scheduled To Present At The 2019 Barclays Global Healthcare Conference

LabCorp® (NYSE: LH) today announced it will participate at the 2019 Barclays Global Healthcare Conference.

LabCorp Strengthens Leadership Position In Precision Medicine With Expansion Of Therapeutic Drug Monitoring Portfolio

LabCorp Strengthens Leadership Position In Precision Medicine With Expansion Of Therapeutic Drug Monitoring Portfolio

LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced a new assay in its therapeutic drug monitoring (TDM) DoseASSURE® portfolio.

LabCorp Announces 2018 Fourth Quarter And Full Year Results And Provides 2019 Guidance

LabCorp Announces 2018 Fourth Quarter And Full Year Results And Provides 2019 Guidance

LabCorp ® (or the Company) (NYSE: LH) today announced results for the fourth quarter and year ended Dec.

LabCorp Named To FORTUNE Magazine's 2019 List Of 'World's Most Admired Companies,' Making The Annual List For The Second Consecutive Year

LabCorp Named To FORTUNE Magazine's 2019 List Of 'World's Most Admired Companies,' Making The Annual List For The Second Consecutive Year

LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to  FORTUNE magazine's 2019 List of World's Most Admired Companies, making the annual list for the second consecutive year.

2 Well-Known Stocks You Should Consider Shorting This Week

2 Well-Known Stocks You Should Consider Shorting This Week

These 'Bearish Bets' are showing both technical and quantitative deterioration.

A Weight Loss Giant, a Maker of Railcars and Other Stocks That Look Good Short

TVTY, DTV, LH, GBX and WTW all recently were downgraded by TheStreet's Quant Ratings.

LabCorp To Announce Fourth Quarter And Full Year 2018 Financial Results On February 7, 2019

LabCorp To Announce Fourth Quarter And Full Year 2018 Financial Results On February 7, 2019

LabCorp® (NYSE: LH) will release its fourth quarter and full year 2018 financial results before the market opens on Thursday, Feb.

Http://www.tachc.org

Http://www.tachc.org

LabCorp® (NYSE: LH) a leading global life sciences company, and the Texas Association of Community Health Centers, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMPH, SNA, ZYME Downgrades: LH, SIMO Initiations: LXFR Read on to get TheStreet Quant Ratings' detailed report:

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

Http://www.genfit.com

Http://www.genfit.com

LabCorp® (NYSE: LH), a leading global life sciences company, and GENFIT (Euronext: GNFT), a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, have announced the signing of a...

LabCorp Is Scheduled To Present At The 37th Annual J.P. Morgan Healthcare Conference

LabCorp Is Scheduled To Present At The 37th Annual J.P. Morgan Healthcare Conference

LabCorp® (NYSE: LH) today announced it will participate at the 37th Annual J.P.

Covance Xcellerate® Wins Best Technological Development In Clinical Trials (Clinical Sponsor-Focused) At 14th Annual Scrip Awards

Covance Xcellerate® Wins Best Technological Development In Clinical Trials (Clinical Sponsor-Focused) At 14th Annual Scrip Awards

LabCorp® (NYSE: LH), a leading global life sciences company, today announced that its Covance Drug Development (Covance) business was awarded Best Technological Development in Clinical Trials (Clinical Sponsor-Focused) at the 14th Annual Scrip Awards for...

L-R, Andrew Fleming, Vice President, Head Of Business Development, Asia Pacific, Covance; Chee Hwee Lim, Vice President, Head Of Clinical Trial Operations, Asia Pacific, Covance. (Photo: Business Wire)

L-R, Andrew Fleming, Vice President, Head Of Business Development, Asia Pacific, Covance; Chee Hwee Lim, Vice President, Head Of Clinical Trial Operations, Asia Pacific, Covance. (Photo: Business Wire)

LabCorp® (NYSE: LH), a leading global life sciences company, today announced that its Covance Drug Development business (Covance) has been awarded the 2018 Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award.

TheStreet Quant Rating: B (Buy)